Cargando…

Dendritic Cell-Based Immunotherapy in Lung Cancer

Lung cancer remains the leading cause of cancer-related death worldwide. The advent of immune checkpoint inhibitors has led to a paradigm shift in the treatment of metastatic non-small cell and small cell lung cancer. However, despite prolonged overall survival, only a minority of the patients deriv...

Descripción completa

Detalles Bibliográficos
Autores principales: Stevens, Dieter, Ingels, Joline, Van Lint, Sandra, Vandekerckhove, Bart, Vermaelen, Karim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928408/
https://www.ncbi.nlm.nih.gov/pubmed/33679709
http://dx.doi.org/10.3389/fimmu.2020.620374
_version_ 1783659850812620800
author Stevens, Dieter
Ingels, Joline
Van Lint, Sandra
Vandekerckhove, Bart
Vermaelen, Karim
author_facet Stevens, Dieter
Ingels, Joline
Van Lint, Sandra
Vandekerckhove, Bart
Vermaelen, Karim
author_sort Stevens, Dieter
collection PubMed
description Lung cancer remains the leading cause of cancer-related death worldwide. The advent of immune checkpoint inhibitors has led to a paradigm shift in the treatment of metastatic non-small cell and small cell lung cancer. However, despite prolonged overall survival, only a minority of the patients derive clinical benefit from these treatments suggesting that the full anti-tumoral potential of the immune system is not being harnessed yet. One way to overcome this problem is to combine immune checkpoint blockade with different strategies aimed at inducing or restoring cellular immunity in a tumor-specific, robust, and durable way. Owing to their unique capacity to initiate and regulate T cell responses, dendritic cells have been extensively explored as tools for immunotherapy in many tumors, including lung cancer. In this review, we provide an update on the nearly twenty years of experience with dendritic cell-based immunotherapy in lung cancer. We summarize the main results from the early phase trials and give an overview of the future perspectives within this field.
format Online
Article
Text
id pubmed-7928408
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79284082021-03-04 Dendritic Cell-Based Immunotherapy in Lung Cancer Stevens, Dieter Ingels, Joline Van Lint, Sandra Vandekerckhove, Bart Vermaelen, Karim Front Immunol Immunology Lung cancer remains the leading cause of cancer-related death worldwide. The advent of immune checkpoint inhibitors has led to a paradigm shift in the treatment of metastatic non-small cell and small cell lung cancer. However, despite prolonged overall survival, only a minority of the patients derive clinical benefit from these treatments suggesting that the full anti-tumoral potential of the immune system is not being harnessed yet. One way to overcome this problem is to combine immune checkpoint blockade with different strategies aimed at inducing or restoring cellular immunity in a tumor-specific, robust, and durable way. Owing to their unique capacity to initiate and regulate T cell responses, dendritic cells have been extensively explored as tools for immunotherapy in many tumors, including lung cancer. In this review, we provide an update on the nearly twenty years of experience with dendritic cell-based immunotherapy in lung cancer. We summarize the main results from the early phase trials and give an overview of the future perspectives within this field. Frontiers Media S.A. 2021-02-12 /pmc/articles/PMC7928408/ /pubmed/33679709 http://dx.doi.org/10.3389/fimmu.2020.620374 Text en Copyright © 2021 Stevens, Ingels, Van Lint, Vandekerckhove and Vermaelen http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Stevens, Dieter
Ingels, Joline
Van Lint, Sandra
Vandekerckhove, Bart
Vermaelen, Karim
Dendritic Cell-Based Immunotherapy in Lung Cancer
title Dendritic Cell-Based Immunotherapy in Lung Cancer
title_full Dendritic Cell-Based Immunotherapy in Lung Cancer
title_fullStr Dendritic Cell-Based Immunotherapy in Lung Cancer
title_full_unstemmed Dendritic Cell-Based Immunotherapy in Lung Cancer
title_short Dendritic Cell-Based Immunotherapy in Lung Cancer
title_sort dendritic cell-based immunotherapy in lung cancer
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928408/
https://www.ncbi.nlm.nih.gov/pubmed/33679709
http://dx.doi.org/10.3389/fimmu.2020.620374
work_keys_str_mv AT stevensdieter dendriticcellbasedimmunotherapyinlungcancer
AT ingelsjoline dendriticcellbasedimmunotherapyinlungcancer
AT vanlintsandra dendriticcellbasedimmunotherapyinlungcancer
AT vandekerckhovebart dendriticcellbasedimmunotherapyinlungcancer
AT vermaelenkarim dendriticcellbasedimmunotherapyinlungcancer